Nasdaq:KZR
Kezar Life Sciences, Inc.
A pre-revenue clinical-stage oncology company advancing its KZT1800 platform with significant cash reserves but facing substantial annual burn rates.
Key Metrics
Investment Thesis
Bull Case
Investors may consider this stock for high-risk exposure to potential breakthrough oncology therapies with a robust pipeline and a strong financial cushion of over $41M in cash. The company's proprietary KZT1800 platform offers unique technological advantages that could lead to significant market penetration if clinical trials are successful.
Bear Case
The absence of revenue and consistent heavy losses make the stock highly speculative with no current path to profitability visible on a traditional basis. With operating expenses nearing $91M annually, the company must secure continuous external capital to survive, creating uncertainty about long-term sustainability without a major strategic transaction.
About Kezar Life Sciences, Inc.
Kezar Life Sciences is a clinical-stage biopharmaceutical company focused on developing novel oncology therapeutics, primarily leveraging its proprietary KZT1800 platform. The company serves the global market with a pipeline of investigational drugs designed to treat various types of cancer by modulating the tumor microenvironment. Currently, the firm operates without commercial revenue, relying entirely on cash reserves and financing activities to fund its extensive research and development efforts.
Analysis
Management Discussion
The company reported a net loss of $83.7M for the latest period, with operating expenses totaling $90.6M driven largely by research and development expenditures of $65.7M. Despite a positive cash flow from investing activities of $80.4M likely due to securities sales, the substantial operating burn rate indicates intense capital requirements typical of clinical-stage ventures.
Industry Overview
Kezar Life Sciences operates in the competitive oncology sector where innovation in immunotherapy and targeted therapies is rapidly evolving. The industry is characterized by high barriers to entry due to regulatory requirements and the necessity for expensive clinical trials before any product can reach market.
Financial Statements
Income Statement
Balance Sheet
Cash Flow
| Metric | 2022 | 2023 | 2024 |
|---|---|---|---|
| Revenue | $0 | $7.0M | $0 |
| Cost of Revenue | $0 | $0 | $0 |
| Gross Profit | $0 | $7.0M | $0 |
| Operating Expenses | $71.2M | $118.4M | $90.6M |
| Operating Income | $-71.2M | $-111.4M | $-90.6M |
| R&D | $51.0M | $85.7M | $65.7M |
| G&A | $20.2M | $26.5M | $23.4M |
| Stock-Based Comp | $14.0M | $18.1M | $13.0M |
| D&A | $1.0M | $1.1M | $1.0M |
| Depreciation | $1.0M | $1.1M | $1.0M |
| Other OpEx | $-1.5M | $6.2M | $1.5M |
| Non-Operating Income | $0 | $0 | $0 |
| Interest Expense | $1.2M | $1.6M | — |
| Interest Income | — | — | $8.5M |
| Pre-Tax Income | $-71.2M | $-111.4M | $-90.6M |
| Income Tax | $0 | $0 | $0 |
| Continuing Ops | $-71.2M | $-111.4M | $-90.6M |
| Discontinued Ops | $0 | $0 | $0 |
| Net Income | $-68.2M | $-101.9M | $-83.7M |
| Minority Interest | $0 | $0 | $0 |
| Net to Common | $-68.2M | $-101.9M | $-83.7M |
| Metric | 2022 | 2023 | 2024 |
|---|---|---|---|
| Current Assets | $285.7M | $206.9M | $137.5M |
| Cash & Equivalents | $40.5M | $35.5M | $41.7M |
| Marketable Securities | $236.1M | $165.9M | $90.5M |
| Prepaid Expenses | — | $5.6M | $5.2M |
| Other Current Assets | $9.2M | $0 | $0 |
| Long-Term Assets | $13.8M | $14.3M | $7.2M |
| PP&E (Net) | $3.4M | $3.9M | $2.9M |
| Operating Leases | $9.7M | $4.8M | $1.9M |
| Other LT Assets | $674.0K | $5.6M | $2.4M |
| Total Assets | $299.6M | $221.2M | $144.7M |
| Current Liabilities | $11.0M | $17.7M | $20.3M |
| Accounts Payable | $2.5M | $8.3M | $3.7M |
| Current Leases | $2.6M | $3.0M | $3.5M |
| Other Current Liab | $0 | $0 | $5.2M |
| Long-Term Liabilities | $18.7M | $15.9M | $7.4M |
| Long-Term Debt | $9.8M | $10.1M | $5.1M |
| LT Operating Leases | $8.9M | $5.9M | $2.3M |
| Other LT Liab | $0 | $0 | $0 |
| Total Liabilities | $29.7M | $33.7M | $27.8M |
| Shareholders' Equity | $269.9M | $187.6M | $116.9M |
| Retained Earnings | $-248.9M | $-350.8M | $-434.5M |
| AOCI | $-923.0K | $-130.0K | $-162.0K |
| Total L&E | $299.6M | $221.2M | $144.7M |
| Metric | 2022 | 2023 | 2024 |
|---|---|---|---|
| Net Income (CFO) | $-68.2M | $-101.9M | $-83.7M |
| Non-Cash Adjustments | $7.2M | $12.5M | $16.2M |
| Working Capital Changes | $2.2M | $7.7M | $-6.7M |
| Cash from Operations | $-58.8M | $-81.6M | $-74.2M |
| Capital Expenditures | $1.6M | $1.8M | $29.0K |
| Cash from Investing | $-91.4M | $76.0M | $80.4M |
| Debt Issuances | $0 | $0 | — |
| Dividends Paid | $0 | $0 | $0 |
| Cash from Financing | $127.9M | $638.0K | $103.0K |
| FX Effect | $-49.0K | $-2.0K | $-63.0K |
| Net Change in Cash | $-22.4M | $-5.0M | $6.3M |
| Beginning Cash | $62.9M | $40.5M | $35.5M |
| Ending Cash | $40.5M | $35.5M | $41.7M |
Frequently Asked Questions
How does Kezar Life Sciences, Inc. make money?
Oncology Therapeutics Development utilizing the KZT1800 platform, Preclinical Research Programs, and Strategic Collaboration Partnerships
What are the main risks for KZR?
Significant operating losses of $83.7M in 2024 with no current revenue streams to offset costs, Heavy reliance on external financing as cash burn outpaces operational income, High regulatory and clinical trial failure risks inherent in early-stage biopharmaceuticals, Limited market capitalization increasing vulnerability to liquidity constraints
What is KZR's competitive advantage?
Proprietary KZT1800 platform technology designed to enhance immune response against tumors, Strong balance sheet with over $41M in cash and equivalents providing runway for clinical trials, Experienced management team with deep expertise in oncology drug development
Related Companies
Not financial advice. All content is for informational purposes only. Data may contain errors. Consult a qualified financial advisor before making investment decisions.